FDA records identify Health Value Creation B.V. (trading as Corporis Medical) as the applicant for K262044, the Mediclose Cartridge System, a Class II endoscopic tissue approximation device under 21 CFR 876.1500 and product code OCW. The submission was received on 17 June 2026 and decided on 14 October 2026 as substantially equivalent, a traditional review not handled by a third party. Corporis Medical’s own site describes Mediclose as a fully integrated suturing solution for trocar-site fascia closure, aimed at a closure step the company says is technically difficult in laparoscopic surgery. [1][2][4]

The applicant and its documented device

The FDA record lists the applicant as Health Value Creation B.V. (trading as Corporis Medical), with a contact named Alexander Veenhof and an address at Oxfordlaan 55, 6229 EV Maastricht, Netherlands. That address appears in the filing; it is not established here as a corporate headquarters. The device is named the Mediclose Cartridge System, classified as an endoscopic tissue approximation device in Class II, regulation 876.1500, product code OCW, with gastroenterology and urology as the medical specialty. [1][9]

Corporis Medical’s published documentation describes Mediclose as a fully integrated suturing solution for trocar-site fascia closure. The company frames the clinical problem around laparoscopic surgery, where small abdominal incisions admit trocars and instruments, and states that reliable fascia closure is technically challenging because of limited access, restricted visibility and fascia elasticity. The same page states that the products are under evaluation and have not received FDA or European regulatory clearance or approval, and are not available for commercial use in the United States or Europe. [4]

Filing scope and review details

The 510(k) database entry for K262044 records a Traditional submission, not reviewed by a third party, not a combination product, and without an authorized predetermined change control plan. A summary is listed as the statement or summary type. The review panel is recorded as General and Plastic Surgery, while the regulation medical specialty is gastroenterology and urology. [2]

The FDA clearance letter for an earlier submission, K213271, addressed to Health Value Creation BV trading as Corporis Medical, names the Mediclose System under regulation 21 CFR 876.1500, Class II, with product codes OCW, GCJ and HCF, and identifies the WECK EFX Endo Fascial Closure System sponsored by Teleflex Medical as the predicate device. That letter is dated 31 August 2023 and concerns a different submission number from K262044. [8]

Company background as published

Corporis Medical’s about page states the company was founded in 2015 by surgeon Alexander Veenhof, MD, and describes a device company that turns operating-room concepts into medical technologies. The same page lists Veenhof as chief executive officer, Josien Landman as chief operating officer and Raoul Beex as chief commercial officer. These are company-published statements, not FDA findings. [6]

The company’s home page describes it as a medical device company developing and commercializing healthcare solutions originating from clinical needs, and carries a link titled FDA approval for Mediclose. The site’s product and home pages also carry a standing notice that the products are under evaluation and have not received FDA or European regulatory clearance or approval. The two statements sit on the same publisher’s pages without reconciliation in the retrieved text. [5]

What the record shows and does not show

The linked FDA collection contains one 510(k) record, K262044, with a single substantially equivalent decision, and the smaller record sample likewise contains that one entry. These are counts of the retrieved filings as of the snapshot date, not measures of total company portfolio, sales or safety performance. No recall records appear in the retrieved sample. [1]

The FDA final-decisions listing for October 2026 includes K262044 as substantially equivalent, published 14 October 2026. Beyond the filings and the manufacturer’s pages, ownership structure, customers, certifications, pricing and commercial availability are not documented in the retrieved material and remain unknown. [7]